These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
144 related articles for article (PubMed ID: 36825217)
1. Buruli-RifDACC: Evaluation of the efficacy and cost-effectiveness of high-dose versus standard-dose rifampicin on outcomes in Amoako YA; Agbanyo A; Novignon J; Owusu L; Tuffour J; Asante-Poku A; Hailemichael Y; Mosweu I; Canter R; Opondo C; Allen E; Pitt C; Yeboah-Manu D; Walker SL; Marks M; Phillips RO; NIHR Open Res; 2022; 2():59. PubMed ID: 36825217 [TBL] [Abstract][Full Text] [Related]
2. Comparison of 8 weeks standard treatment (rifampicin plus clarithromycin) vs. 4 weeks standard plus amoxicillin/clavulanate treatment [RC8 vs. RCA4] to shorten Buruli ulcer disease therapy (the BLMs4BU trial): study protocol for a randomized controlled multi-centre trial in Benin. Johnson RC; Sáez-López E; Anagonou ES; Kpoton GG; Ayelo AG; Gnimavo RS; Mignanwande FZ; Houezo JG; Sopoh GE; Addo J; Orford L; Vlasakakis G; Biswas N; Calderon F; Della Pasqua O; Gine-March A; Herrador Z; Mendoza-Losana A; Díez G; Cruz I; Ramón-García S Trials; 2022 Jul; 23(1):559. PubMed ID: 35804454 [TBL] [Abstract][Full Text] [Related]
3. Drugs for treating Buruli ulcer (Mycobacterium ulcerans disease). Yotsu RR; Richardson M; Ishii N Cochrane Database Syst Rev; 2018 Aug; 8(8):CD012118. PubMed ID: 30136733 [TBL] [Abstract][Full Text] [Related]
4. Rifampicin and clarithromycin (extended release) versus rifampicin and streptomycin for limited Buruli ulcer lesions: a randomised, open-label, non-inferiority phase 3 trial. Phillips RO; Robert J; Abass KM; Thompson W; Sarfo FS; Wilson T; Sarpong G; Gateau T; Chauty A; Omollo R; Ochieng Otieno M; Egondi TW; Ampadu EO; Agossadou D; Marion E; Ganlonon L; Wansbrough-Jones M; Grosset J; Macdonald JM; Treadwell T; Saunderson P; Paintsil A; Lehman L; Frimpong M; Sarpong NF; Saizonou R; Tiendrebeogo A; Ohene SA; Stienstra Y; Asiedu KB; van der Werf TS; Lancet; 2020 Apr; 395(10232):1259-1267. PubMed ID: 32171422 [TBL] [Abstract][Full Text] [Related]
5. Dressings and topical agents for the management of open wounds after surgical treatment for sacrococcygeal pilonidal sinus. Herrod PJ; Doleman B; Hardy EJ; Hardy P; Maloney T; Williams JP; Lund JN Cochrane Database Syst Rev; 2022 May; 5(5):CD013439. PubMed ID: 35593897 [TBL] [Abstract][Full Text] [Related]
6. The Application of Modern Dressings to Buruli Ulcers: Results from a Pilot Implementation Project in Ghana. Velding K; Klis SA; Abass KM; van der Werf TS; Stienstra Y Am J Trop Med Hyg; 2016 Jul; 95(1):60-2. PubMed ID: 27162271 [TBL] [Abstract][Full Text] [Related]
7. Adhesion of the ulcerative pathogen Mycobacterium ulcerans to DACC-coated dressings. Geroult S; Phillips RO; Demangel C J Wound Care; 2014 Aug; 23(8):417-8, 422-4. PubMed ID: 25139600 [TBL] [Abstract][Full Text] [Related]
8. Negative-pressure wound therapy compared with standard dressings following surgical treatment of major trauma to the lower limb: the WHiST RCT. Costa ML; Achten J; Knight R; Png ME; Bruce J; Dutton S; Madan J; Vadher K; Dritsaki M; Masters J; Spoors L; Campolier M; Parsons N; Fernandez M; Jones S; Grant R; Nanchahal J Health Technol Assess; 2020 Aug; 24(38):1-86. PubMed ID: 32821038 [TBL] [Abstract][Full Text] [Related]
9. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas. Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557 [TBL] [Abstract][Full Text] [Related]
11. Dressings and topical agents for treating pressure ulcers. Westby MJ; Dumville JC; Soares MO; Stubbs N; Norman G Cochrane Database Syst Rev; 2017 Jun; 6(6):CD011947. PubMed ID: 28639707 [TBL] [Abstract][Full Text] [Related]
12. Early versus deferred endovenous ablation of superficial venous reflux in patients with venous ulceration: the EVRA RCT. Gohel MS; Heatley F; Liu X; Bradbury A; Bulbulia R; Cullum N; Epstein DM; Nyamekye I; Poskitt KR; Renton S; Warwick J; Davies AH Health Technol Assess; 2019 May; 23(24):1-96. PubMed ID: 31140402 [TBL] [Abstract][Full Text] [Related]
13. Effectiveness of rifampicin-streptomycin for treatment of Buruli ulcer: a systematic review. Tanywe A; Fernandez RS JBI Database System Rev Implement Rep; 2017 Jan; 15(1):119-139. PubMed ID: 28085731 [TBL] [Abstract][Full Text] [Related]
14. Assessing the effectiveness of dialkylcarbamoylchloride (DACC)-coated post-operative dressings versus standard care in the prevention of surgical site infection in clean or clean-contaminated, vascular surgery (the DRESSINg trial): study protocol for a pilot feasibility randomised controlled trial. Totty JP; Harwood AE; Cai PL; Hitchman LH; Smith GE; Chetter IC Pilot Feasibility Stud; 2019; 5():11. PubMed ID: 30680225 [TBL] [Abstract][Full Text] [Related]
15. Randomised controlled trial of the use of three dressing preparations in the management of chronic ulceration of the foot in diabetes. Jeffcoate WJ; Price PE; Phillips CJ; Game FL; Mudge E; Davies S; Amery CM; Edmonds ME; Gibby OM; Johnson AB; Jones GR; Masson E; Patmore JE; Price D; Rayman G; Harding KG Health Technol Assess; 2009 Nov; 13(54):1-86, iii-iv. PubMed ID: 19922726 [TBL] [Abstract][Full Text] [Related]
16. Microbiology of secondary infections in Buruli ulcer lesions; implications for therapeutic interventions. Gyamfi E; Narh CA; Quaye C; Abbass A; Dzudzor B; Mosi L BMC Microbiol; 2021 Jan; 21(1):4. PubMed ID: 33402095 [TBL] [Abstract][Full Text] [Related]
17. Topical antimicrobial agents for treating foot ulcers in people with diabetes. Dumville JC; Lipsky BA; Hoey C; Cruciani M; Fiscon M; Xia J Cochrane Database Syst Rev; 2017 Jun; 6(6):CD011038. PubMed ID: 28613416 [TBL] [Abstract][Full Text] [Related]